Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3027 vs DUPIXENT in Healthy Adult Chinese Male Volunteers
NCT07502534Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3027 in atopic dermatitis (AD) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Peak drug concentration and Area under the plasma concentration-time curve from time zero to infinity. Started Apr 2026; status: active, not recruiting.
02
Drugs
IBI3027
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07502534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502534.